

Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

CD279

RRID:AB_10895570

Type: Antibody

Proper Citation

BD Biosciences Cat# 561788, RRID:AB_10895570

Antibody Information

URL: http://antibodyregistry.org/AB_10895570

Proper Citation: BD Biosciences Cat# 561788, RRID:AB_10895570

Target Antigen: CD279 (PD-1)

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD279

Description: This monoclonal targets CD279 (PD-1)

Target Organism: mouse

Antibody ID: AB_10895570

Vendor: BD Biosciences

Catalog Number: 561788

Record Creation Time: 20250819T235824+0000

Record Last Update: 20250820T065939+0000

Ratings and Alerts

No rating or validation information has been found for CD279.

No alerts have been found for CD279.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Budina E, et al. (2025) Activity-attenuated serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitis. *Cell reports. Medicine*, 6(7), 102231.

Kim HC, et al. (2025) Gut microbiota dysbiosis induced by brain tumors modulates the efficacy of immunotherapy. *Cell reports*, 44(7), 115825.

Mittal S, et al. (2024) Protocol for the isolation of tumor cell-derived extracellular vesicles followed by in?vivo metastasis assessment in a murine ovarian cancer model. *STAR protocols*, 5(2), 102943.

Li J, et al. (2024) Amitriptyline revitalizes ICB response via dually inhibiting Kyn/Indole and 5-HT pathways of tryptophan metabolism in ovarian cancer. *iScience*, 27(12), 111488.

Wu SY, et al. (2023) CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. *Med (New York, N.Y.)*, 4(6), 373.